Clinical trials: Ischemic Cardiopathy
ST Elevation Myocardial Infarction
A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)
This is an exploratory, randomized, double-blind, multicentre, placebo-controlled study of RTP-026. The study population will consist of men and women with documented evidence of ST-elevation myocardial infarction (STEMI)…
- Trial name
- NCT06465303
- Testing
- RTP-026
- Where
- Denmark
- Volunteers
- 66 people
- Sponsor
- ResoTher Pharma
Coronary Stenosis
Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent
The primary objective of this study is to compare the performance of SUPRAFLEX to that of XIENCE in an all-comers patient population with symptomatic ischemic heart disease.
- Trial name
- TALENT (NCT02870140)
- Testing
- SUPRAFLEX, XIENCE
- Where
- 23 sites in Bulgaria, Hungary and 5 more
- Volunteers
- 1,435 people
- Sponsor
- ECRI bv
Patent Foramen Ovale
Paradigm I Clinical Trial: Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism
The primary objective of this study is to demonstrate the safety of the PFX Closure System when utilized for patients with patent foramen ovale (PFO) suffering from cryptogenic stroke, transient ischemic attacks or paradoxical…
- Trial name
- NCT00196027
- Testing
- PFX Closure System
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cierra
Acute Anterior ST-Segment Elevation Myocardial Infarction
A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction
This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of SGC001 injection administered in addition to…
- Trial name
- NCT07306182
- Testing
- SGC001 injection
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Beijing Sungen Biomedical Technology Co., Ltd
Coronary Heart Disease, Stable Angina Pectoris
BuMA OCT Study(A Comparative Evaluation of the Extent of Neointima Formation at 3 Months After Implantation Using OCT)
The objective of this study is a comparative evaluation of BuMA stent and of EXCEL stent in terms of the extent of neointima formation at 3 months after implantation using OCT.
- Conditions
- Coronary Heart Disease, Stable Angina Pectoris, Unstable Angina Pectoris, Silent Myocardial Ischemia
- Trial name
- NCT01752582
- Testing
- BuMA stent, EXCEL stent
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Coronary Artery Disease
Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial
The purpose of this study is to evaluate new generation drug eluting stent (DES) of MicroPort of its safety, efficacy and delivery system in treating CAD.
- Trial name
- NCT01196819
- Testing
- Firehawk, Xience V
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease Obliterative, Chronic Total Occlusion (CTO)
A Prospective, Non-Randomized Pivotal Clinical Investigation to Demonstrate the Safety and Performance of the TrueCross Single-Use Microcatheter
The trial is a pivotal clinical investigation, which is a prospective, non-randomized pivotal clinical investigation to demonstrate the safety and performance of the TrueCross Single-use Microcatheter.
- Trial name
- NCT06030271
- Testing
- Microcatheter
- Where
- 7 sites in Georgia, Greece and 1 more
- Volunteers
- 60 people
- Sponsor
- Insight Lifetech Co., Ltd.
Acute Coronary Syndrome
IDE-ALERTS Continued Access Study
This Continued Access IDE Study includes a subset of former ALERTS trial (NCT00781118) patients and provides performance data for a refined Guardian implantable medical device (AMSG3-E) with a new battery designed to extend…
- Trial name
- ALERTS-CAS (NCT04316481)
- Testing
- AngelMed Guardian System
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Angel Medical Systems
Coronary Artery Disease
Cobra II Study: Use of the Cobra™ Cobalt Super Alloy Coronary Stent System in the Treatment of Coronary Artery Disease
To demonstrate the safety and efficacy of the Cobra Cobalt Super Alloy Balloon-Expandable Coronary Stent System for the treatment of de novo and restenotic (previously unstented) lesions in native coronary arteries in subjects…
- Trial name
- NCT00744107
- Testing
- PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System
- Where
- 7 sites in Germany, Israel and 2 more
- Volunteers
- 258 people
- Sponsor
- Medlogics Device Corporation
Coronary Artery Disease
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM SV (NCT01498692)
- Testing
- PROMUS Element Coronary Stent System
- Where
- 23 sites in United States, Australia and 4 more
- Volunteers
- 94 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Detection of Coronary Artery Disease Using Analysis of High Frequency QRS: The HyperQ Registry
This will be a registry study that will enroll patients referred for an ECG treadmill test with nuclear myocardial perfusion imaging (MPI).
- Trial name
- HyperQ (NCT01325467)
- Where
- 3 sites in United States
- Volunteers
- 900 people
- Sponsor
- BSP Biological Signal Processing Ltd.
Coronary (Artery); Disease
Trial of MiStent Compared to Xience in Japan
To compare the MT005 (MiStent) with the XIENCE with respect to target lesion failure (TLF) at 12 months in a non-inferiority trial in a "real world" patient population and to confirm that the domestic extrapolation of the…
- Trial name
- DESSOLVEJ (NCT02972671)
- Testing
- MiStent (MT005) Coronary Artery Stent, Xience Coronary Artery Stent
- Where
- 10 sites in Japan
- Volunteers
- 120 people
- Sponsor
- Micell Technologies
Peripheral Vascular Diseases, Coronary Artery Disease
Single Arm, Prospective, Open-label, Multi-center Clinical Investigation for the Demax Guide Wire
The objectives of this study are to confirm the safety and performance of the Guide Wire when used in patients with peripheral vascular or coronary vascular disease for diagnostic or treatment procedures and will be the pivotal…
- Trial name
- SPOMCIDGW (NCT06735846)
- Testing
- Guide wire
- Volunteers
- 100 people
- Sponsor
- DemaxGroup
Acute Coronary Syndromes
Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction
The purpose of this study is to determine if the combination of aspirin plus clopidogrel is more effective than aspirin alone in preventing another heart attack, chest pain, stroke or death in people who have already had a heart…
- Trial name
- CLARITY-TIMI28 (NCT00714961)
- Testing
- Clopidogrel (SR25990)
- Where
- 24 sites in United States, Argentina and 22 more
- Volunteers
- 3,491 people
- Sponsor
- Sanofi
Coronary Atherosclerosis
Bifurcation Lesion Analysis and STenting / BLAST
The purpose of this research study is to determine if Intravascular Ultrasound (IVUS) grayscale and VH (Virtual Histology)-IVUS pre-stenting can assess more accurately the location, amount, and type of a blockage than angiogram…
- Trial name
- BLAST (NCT02316782)
- Testing
- Blinded IVUS assessment, Nonblinded IVUS
- Where
- 10 sites in United States, Denmark and 6 more
- Volunteers
- 195 people
- Sponsor
- Volcano Corporation
Essential Hypertension, Chronic Stable Angina
Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg
The purpose of this study is to compare the pharmacokinetic characteristics and safety of dilatrend SR capsule 32mg and Dilatrend tablet 25mg in healthy male subjects.
- Conditions
- Essential Hypertension, Chronic Stable Angina, Congestive Heart Failure
- Trial name
- NCT01819870
- Testing
- Dilatrend SR capsule 32mg, Dilatrend IR tablet 25mg
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Angina Pectoris, Coronary Heart Disease
Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction
Objective to evaluate the effect of Shexiang Baoxin Pill on myocardial ischemia in patients with coronary microvascular dysfunction (non obstructive coronary heart disease) through a randomized, double-blind, placebo-controlled…
- Conditions
- Angina Pectoris, Coronary Heart Disease, X Syndrome, Angina, Non Obstructive Coronary Artery Disease
- Trial name
- NCT04984954
- Testing
- MUSK pill
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Atrial Fibrillation, Stroke
WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation
This is a multi-center, prospective, randomized study, stratified by center, comparing the WATCHMAN device to long term warfarin therapy, demonstrating that the treatment arm is non-inferior to the control arm.
- Trial name
- NCT00129545
- Testing
- WATCHMAN Left Atrial Appendage Closure Technology, Warfarin
- Where
- 62 sites in United States, Czechia and 1 more
- Volunteers
- 800 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study
The DynamX (Bioadaptor) study is a prospective, consecutive enrollment study designed to enroll up to 50 patients requiring treatment of a single, de novo lesion ≤ 24 mm in length located in a vessel ≥ 2.5 mm and ≤ 3.5 mm in…
- Trial name
- NCT03429894
- Testing
- Percutaneous Coronary Intervention
- Where
- 2 sites in Belgium, Italy
- Volunteers
- 50 people
- Sponsor
- Elixir Medical Corporation
Acute Coronary Syndrome, Type 2 Diabetes
A Phase 2 Study to Determine the Effects of BXT-51072 in Diabetic Patients Undergoing Angioplasty (PCI)
The purpose of this study is to determine the safety and feasibility of BXT-51072 as a cardioprotective agent in diabetics undergoing elective angioplasty / percutaneous intervention (PCI), a procedure to "open" coronary…
- Trial name
- NCT00320502
- Testing
- BXT-51072
- Where
- 4 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Synvista Therapeutics, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.